The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
3 - If there are more than two studies that show the same outcome (e.g.: Improved BP reduction Vs a competing ARB) then do we still ask for disclosure of study parameters? Code s5.11 says this should not be required.
Disclosure requirements: PI & Safety Information, Federal schedule, study parameters, reference lists
1
Posts
1
Posters
288
Views
1
Watching
-
Code s5.11 goes on to say that 'In no circumstances would extrapolation of the claim beyond the actual study be acceptable'. Often, if one does not specify the population (e.g.: men in a cholesterol agent comparison) then the reader might extrapolate the study results beyond the evaluated population. This would be true even if you had 50 studies showing the same result. Important information such as this should not be put in mice-type.
